Skip to content

Sub-classification and oncogenic network analysis of ALDH1A3-positive pancreatic ductal adenocarcinoma

Sub-classification and oncogenic network analysis of ALDH1A3-positive pancreatic ductal adenocarcinoma

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043187
Enrollment
Unknown
Registered
2021-02-08
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductal adenocarcinoma

Interventions

case series:Nil

Sponsors

The Affiliated Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years old; 2. Patients with pancreatic ductal adenocarcinoma confirmed by postoperative pathology; 3. Patients who did not receive chemoradiotherapy or other anti-tumor therapy before operation; 4. Patients who were followed up for more than 24 months; 5. Patients who have signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with other types of pancreatic cancer; 2. Patients with other tumors; 3. Patients with incomplete clinical information.

Design outcomes

Primary

MeasureTime frame
computed tomography;tumor markers;overall survival;

Countries

China

Contacts

Public ContactXiaoping Zou

The Affiliated Drum Tower Hospital of Nanjing University Medical School

13770771661@163.com+86 13770771661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026